https://orcid.org/0000-0003-0261-616X
References
- Berger, R. L., and Hsu, J. C. (1996), “Bioequivalence Trials, Intersection-Union Tests and Equivalence Confidence Sets,” Statistical Science, 11, 283–319. DOI: 10.1214/ss/1032280304.
- Brannath, W., Posch, M., and Bauer, P. (2002), “Recursive Combination Tests,” Journal of the American Statistical Association, 97, 236–244. DOI: 10.1198/016214502753479374.
- Genz, A., Bretz, F., Miwa, T., Mi, X., Leisch, F., Scheipl, F., and Hothorn, T. (2021), mvtnorm: Multivariate Normal and t Distributions. R package version 1.1-2. Available at https://CRAN.R-project.org/package=mvtnorm.
- Hsiao, S. T., Liu, L., and Mehta, C. R. (2019), “Optimal Promising Zone Designs,” Biometrical Journal, 5, 1175–1186. DOI: 10.1002/bimj.201700308.
- Jennison, C., and Turnbull, B. (2000), Group Sequential Methods with Applications to Clinical Trials, Boca Raton, FL: Chapman & Hall/CRC Press.
- Kaza, M., Sokolovskyi, A., and Rudzki, P. J. (2020), “10th Anniversary of a Two-Stage Design In Bioequivalence. Why Has It Still Not Been Implemented?” Pharmaceutical Research, 37, 140. DOI: 10.1007/s11095-020-02871-3.
- Labes, D., Lang, B., and Schütz, H. (2021), Power2Stage: Power and Sample-Size Distribution of 2-Stage Bioequivalence Studies, R package version 0.5-4. Available at https://CRAN.R-project.org/package=Power2Stage
- Maurer, W., Jones, B., and Ying, C. (2018), “Controlling the Type I Error Rate in Two-Stage Sequential Adaptive Designs When Testing for Average Bioequivalence,” Statistics in Medicine, 37, 1587–1607. DOI: 10.1002/sim.7614.
- Pallmann, P., and Jaki, T. (2017), “Simultaneous Confidence Regions for Multivariate Bioequivalence,” Statistics in Medicine, 36, 4585–4603. DOI: 10.1002/sim.7446.
- Patterson, S., and Jones, B. (2017), Bioequivalence and Statistics in Clinical Pharmacology (2nd ed.), Boca Raton, FL: CRC Press.
- Potvin, D., DiLiberti, C. E., Hauck, W. W., Parr, A. F., Schuirmann, D. J., and Smith, R. A. (2008), “Sequential Design Approaches for Bioequivalence Studies with Crossover Designs,” Pharmaceutical Statistics, 7, 245–262. DOI: 10.1002/pst.294.
- U.S. Food and Drug Administration (2019), “Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry.”
- U.S. Food and Drug Administration Draft Guidance (2021), “Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA Guidance for Industry.”
- Wassmer, G., and Brannath, W. (2016), Group Sequential and Confirmatory Adaptive Designs in Clinical Trials, Cham: Springer.